CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 345 enrolled
Drug / intervention
Zabofloxacin +1 moredrug
Likely dose
Zabofloxacin 367mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01658020
NCT01658020Phase 3Completed

Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.

Dong Wha Pharmaceutical Co. Ltd.·interventional·Posted Aug 6, 2012·Updated Oct 13, 2014

In Brief

A Phase 3 clinical trial evaluating Zabofloxacin and Moxifloxacin for Chronic Obstructive Pulmonary Disease. Completed, enrolled 345 participants across 1 site.

Detailed Summary

The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.

Study Details

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 6, 2012
Enrollment StartAug 1, 2012
Primary CompletionJan 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.9 years ago

Interventions

Zabofloxacindrug

Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days

Moxifloxacindrug

Moxifloxacin 400mg tablet P.O. once daily for 7days